infusion of ADR-001 (Mesenchymal stem cell)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis , IGA
Conditions
Glomerulonephritis , IGA
Trial Timeline
Jun 15, 2020 → Mar 31, 2023
NCT ID
NCT04342325About infusion of ADR-001 (Mesenchymal stem cell)
infusion of ADR-001 (Mesenchymal stem cell) is a phase 1 stage product being developed by Rohto Pharmaceutical for Glomerulonephritis , IGA. The current trial status is completed. This product is registered under clinical trial identifier NCT04342325. Target conditions include Glomerulonephritis , IGA.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04342325 | Phase 1 | Completed |
Competing Products
8 competing products in Glomerulonephritis , IGA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |